Image

The Influencing Factors and Prediction Model of Poor Prognosis of Spontaneous Intraparenchymal Hemorrhage

The Influencing Factors and Prediction Model of Poor Prognosis of Spontaneous Intraparenchymal Hemorrhage

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

This study was designed to explore the influencing factors of spontaneous intraparenchymal hemorrhage's prognosis and develop predictive models for poor prognosis by establishing a cohort of spontaneous intraparenchymal hemorrhage (including both of the supratentorial intracerebral hemorrhage and cerebellar hemorrhage), and analyzing the correlation between collected variables and patients' outcomes.

Description

Spontaneous intracranial hemorrhage is an important type of cerebrovascular disease. The disease has an acute onset, a serious condition, and a high mortality rate. Besides, the survivors always live with severe neurological dysfunction. It is essential to determine the influencing factors of poor prognosis, estimate patient's condition and predict the prognosis timely.

This study consists of two parts. The first part establishes a cohort of spontaneous intraparenchymal hemorrhage (including both of the supratentorial intracerebral hemorrhage and cerebellar hemorrhage), and analyzes the influence of different factors, such as surgical methods, on the prognosis. In the second part, a nested case-control study nested in this cohort will be established to analyse the influence of some other factors. The biological specimens are tested. The collected data were analysed to find out the risk factors of poor prognosis and establish a predictive model.

Recruitment and follow-up of the participants is expected to continue after the initial goal is achieved. As a large sample database of intracranial hemorrhage, this cohort will provide more research data for the future exploration of more clinical problems.

Eligibility

Inclusion Criteria:

  1. Age 18-80;
  2. Diagnosed with spontaneous intraparenchymal hemorrhage (both of the supratentorial intracerebral hemorrhage and cerebellar hemorrhage) by Computed Tomography;
  3. Admitted within 24h of ictus;
  4. Did not undertake treatment before enrollment;
  5. Informed consent to participate in the study.

Exclusion Criteria:

  1. The hemorrhage caused by tumor, arteriovenous malformation, aneurysm or coagulopathy;
  2. Concurrent traumatic brain injury;
  3. Multiple intracerebral hemorrhage;
  4. Undertake any surgery after onset in other hospital;
  5. Refuse the treatment after admission;
  6. History of craniocerebral surgery;
  7. Known advanced demential or disability before onset;
  8. Any concurrent serious illness that would interfere with the safety assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease;
  9. Confirmed malignant disease or life expectancy less than 6 months due to comorbid diseases;
  10. Concurrent serious infectious disease (HIV, tuberculosis etc.)
  11. Concurrent coagulation disorders or having taken anti-platelet or anticoagulant drugs;
  12. With indications of terminal brain hernia
  13. Pregnant or lactating females;
  14. Participation in another simultaneous trial of intracerebral hemorrhage treatment;
  15. Patients/relatives refuse to be followed up。

Study details
    Spontaneous Intracranial Hemorrhage
    Spontaneous Intraparenchymal Cerebral Hemorrhage
    Spontaneous Cerebellar Haemorrhage

NCT03899350

Tang-Du Hospital

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.